Study compares high-dose IL-2 and HDAC inhibitor entinostat to IL-2 alone
A phase II, open label study for patients with renal cell carcinoma (RCC), the most common type of kidney cancer, is currently enrolling subjects at […]
A phase II, open label study for patients with renal cell carcinoma (RCC), the most common type of kidney cancer, is currently enrolling subjects at […]
This month, Hoosier Cancer Research Network highlights the University of Kansas Medical Center as a featured member of our network. Anup Kasi, MD, MPH, assistant […]
This month, Hoosier Cancer Research Network highlights the Providence Cancer Institute in Portland, Ore., as a featured member of our network. Rachel E. Sanborn, MD, […]
Indiana University School of Medicine researchers have discovered how to predict whether triple negative breast cancer will recur, and which women are likely to remain […]
Hoosier Cancer Research Network (HCRN) Executive Director Cyndi Burkhardt, RN, will speak during the Onsemble Conference, September 18-21 in Madison, Wis., and Assistant Director for […]
Cancer research, as complex and technical an endeavor as it is, involves real people, and no matter what resources are expended, it is the human […]
“Cancer is the best thing that ever happened to me. It certainly changed my life for the better.” This perspective, shared by cancer research advocate […]
“With cancer comes recognition of the fact that death is real, that you only are blest with so many days, and you only have so […]
This spring, Hoosier Cancer Research Network Chairman Christopher A. Fausel, PharmD, invited friends and colleagues to join him in a unique challenge called Reps for […]
Hoosier Cancer Research Network, formerly known as Hoosier Oncology Group, recently honored Olumide Gbolahan, MD, as the 2016 recipient of the George and Sarah Jane Fisher […]
The Sandra Turner Excellence in Clinical Research Award was established in 2002 by Dr. William B. Fisher through the George and Sarah Jane Fisher Fund […]
The Indiana University Melvin and Bren Simon Cancer Center hosted Doug Lowy, the acting director of the National Cancer Institute, for a full-day visit on […]
The Indiana University School of Medicine will host the Andrea Gianaris Pancreatic Cancer Symposium on Thursday, Nov. 16, 8 a.m. to 12:30 p.m. in Walther […]
Investigators working on the HCRN LUN14-179 study, which involved the use of concurrent chemoradiation with consolidation pembrolizumab for unresectable stage III non-small cell lung cancer, […]
Hoosier Cancer Research Network honored four individuals for their outstanding contributions to clinical research and advocacy during its annual holiday and awards dinner Nov. 30 […]
For the fourth consecutive year, Hoosier Cancer Research Network chairman Christopher A. Fausel, PharmD, is encouraging his friends, colleagues, and local businesses to support HCRN […]
A Phase II Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer HCRN: GI16-288 Status: Closed to […]
This month, Hoosier Cancer Research Network (HCRN) features our member University of Virginia Cancer Center and Ryan Gentzler, MD, MS, a thoracic medical oncologist and […]
A remarkable thing happens when someone contributes to a cause bigger than oneself. But even more profound is the call to do so. That this […]
2017 was an extraordinary year of growth for HCRN — both in terms of numbers and in the quality of engagement with our network collaborators. […]
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter